Holen Sie sich die Stockscreener-App
0.4256
3.10%
-0.0136
Schlusskurs vom Vortag:
$0.4392
Offen:
$0.4409
24-Stunden-Volumen:
358.53K
Relative Volume:
0.51
Marktkapitalisierung:
$25.70M
Einnahmen:
$2.29M
Nettoeinkommen (Verlust:
$-18.63M
KGV:
-0.7574
EPS:
-0.5619
Netto-Cashflow:
$-19.32M
1W Leistung:
+13.19%
1M Leistung:
-19.70%
6M Leistung:
-49.29%
1J Leistung:
-64.24%
1-Tages-Spanne:
$0.4182
$0.4567
1-Wochen-Bereich:
$0.36
$0.4567
52-Wochen-Spanne:
$0.3067
$1.29
Femasys Inc Stock (FEMY) Company Profile
Firmenname
Femasys Inc
Sektor
Telefon
770-500-3910
Adresse
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.4255 | 26.52M | 2.29M | -18.63M | -19.32M | -0.5619 |
ISRG
Intuitive Surgical Inc
|
451.71 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.99 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.52 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
43.77 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
223.75 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Laidlaw | Buy |
Femasys Inc Aktie (FEMY) Neueste Nachrichten
Femasys appoints John Canning as COO - MSN
Femasys Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Femasys names John Canning as chief operating officer By Investing.com - Investing.com Australia
FEMASYS (FEMY) COO awarded 150,000 stock options at $0.38 exercise price - Stock Titan
Femasys (FEMY) COO John Canning discloses ownership of 30,000 shares - Stock Titan
Femasys Names John Canning as New Chief Operating Officer - TipRanks
Femasys Inc. Appoints John Canning as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth - bitget.com
Femasys names John Canning as chief operating officer - Investing.com
Femasys names John Canning as Chief Operating Officer - TradingView
Veteran MedTech leader John Canning joins Femasys (NASDAQ: FEMY) as COO - Stock Titan
Femasys earnings beat by $0.12, revenue fell short of estimates - ca.investing.com
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - National Today
Femasys 2025 10-K: Revenue $2.29M, Net loss per share $(0.47) - TradingView
Femasys (NASDAQ: FEMY) advances FemBloc and FemaSeed women’s health platform - Stock Titan
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Femasys 2025 sales jump on FemBloc demand - TradingView
Femasys (NASDAQ: FEMY) details 2025 results and FemBloc FINALE trial - Stock Titan
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Femasys Inc (FEMY) Earnings Calendar_Earnings Analysis_Financial Report and Earnings Call - Tiger Brokers
FEMY Should I Buy - Intellectia AI
Femasys (FEMY) CFO receives 34,122 Series D-1 warrants at $0.58 - Stock Titan
Femasys (NASDAQ: FEMY) director awarded 34,122 Series D-1 warrants - Stock Titan
Board seeks reverse split, Nasdaq‑rule approval for issuances (FEMY) - Stock Titan
Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan
Femasys amends warrants and notes, appoints new director to board By Investing.com - Investing.com India
Femasys Inc. Enters Omnibus Amendment and Issues Series D-1 Warrants – SEC 8-K Filing March 2026 - Minichart
Femasys amends warrants and notes, appoints new director to board - Investing.com
Femasys (NASDAQ: FEMY) director receives stock options for 35,200 shares - Stock Titan
Femasys Amends Financing Terms and Issues New Warrants - TipRanks
Femasys enters omnibus amendment and consent agreement on March 19, 2026SEC filing - MarketScreener
Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026SEC Filing - TradingView
Femasys Amends Notes and Warrants; Issues 16.38M New Warrants at $0.58 to Holders - TradingView
Femasys (FEMY) grants 16.4M Series D-1 warrants and appoints new independent director - Stock Titan
Femasys Inc. announced that it has received $12 million in funding - marketscreener.com
Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com South Africa
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
Femasys (NASDAQ: FEMY) director Joshua Silverman files neutral Form 4 - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
Femasys Inc. Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - marketscreener.com
Femasys appoints anesthesiologist to board of directors - Investing.com
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Bitget
Femasys Inc. Appoints Kenneth D. Eichenbaum, M.D., M.S.E., to Board of Directors - Quiver Quantitative
Femasys appoints Dr. Kenneth D. Eichenbaum to board of directors - marketscreener.com
Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors - TradingView
Femasys begins enrollment in pivotal trial for FemBloc device - Investing.com Nigeria
Jeremy Alexander Sipos Net Worth (2026) - GuruFocus
Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges - MSN
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing - MSN
Finanzdaten der Femasys Inc-Aktie (FEMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.73%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):